Kaposi's sarcoma-associated herpesvirus (KSHV) has been consistently identified in Kaposi's sarcoma (KS) tumors, pleural effusion lymphomas, and multicentric Castleman's diseases. While there is a reduction in the incidence of KS among patients receiving HAART, an increasing concern is the development and spread of drug resistant HIV-1 strains, which in turn leads to reoccurrence of KSHV-associated malignancy. Despite being this pressing human health problem, however, very little has been done thus far to study host's immune responses and potential vaccine development against KSHV infection and its associated diseases. This is primarily because of the lack of proper genetic system and animal model that support in vivo studies on KSHV replication, persistence, and pathogenesis. We have recently established a new "infectious" bacterial artificial clone of KSHV genome (BAC16) that significantly improved the efficiency of the genetic manipulation and virus production system. Besides this, we have also established the first successful zoonotic or cross-species transmission of KSHV into non-human primates, common marmosets (Callithrix jacchus). Our specific preliminary results are: (1) the KSHV BAC16 is stable and produce infectious virus (~106-7 titers);(2) common marmosets intravenously or orally inoculated with recombinant KSHV rapidly sero-converted and maintained a high anti-KSHV antibody response over a long period of time;and (3) remarkably, orally infected marmoset developed KS-like skin lesions with the characteristic infiltration of leukocytes by spindle cells positive for KSHV DNA and proteins. These genetic and animal models significantly recapitulate the important aspects of KSHV infection in humans, thus providing a unique opportunity in developing potential vaccine strategies against KSHV infection. Thus, recombinant viruses will be constructed to determine their roles in viral infection in cultures, mice, and primates, and ultimately establish the foundations for the rationale design of vaccine candidates. Thus, the goal of this study is two-fold: firstly, to develop genetically modified KSHV strains to be used as vaccine candidates and secondly, to further build up the animal models of KSHV infection for vaccine development. This proposal is highly innovative and a successful outcome should prove to be a major discovery that significantly impacts the understanding of KSHV infection to ultimately reveal novel protective and/or therapeutic vaccine strategies.
Kaposi's sarcoma-associated herpesvirus (KSHV) has been consistently identified in Kaposi's sarcoma tumors, primary effusion lymphoma, and Multicentric Castleman's disease. Despite being a pressing human health problem, there has been little or no activity so far to develop protective and/or therapeutic vaccines against KSHV infection and its associated diseases. This proposal is highly innovative and a successful outcome should prove to be a major discovery that significantly impacts the understanding of the controls of KSHV infection to ultimately reveal novel protective and/or therapeutic vaccine strategies.
|Brulois, Kevin; Wong, Lai-Yee; Lee, Hye-Ra et al. (2015) Association of Kaposi's Sarcoma-Associated Herpesvirus ORF31 with ORF34 and ORF24 Is Critical for Late Gene Expression. J Virol 89:6148-54|
|Liang, Qiming; Chang, Brian; Lee, Patrick et al. (2015) Identification of the Essential Role of Viral Bcl-2 for Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication. J Virol 89:5308-17|
|Lee, Hye-Ra; Amatya, Rina; Jung, Jae U (2015) Multi-step regulation of innate immune signaling by Kaposi's sarcoma-associated herpesvirus. Virus Res 209:39-44|
|Brulois, Kevin; Jung, Jae U (2014) Interplay between Kaposi's sarcoma-associated herpesvirus and the innate immune system. Cytokine Growth Factor Rev 25:597-609|
|Liang, Qiming; Seo, Gil Ju; Choi, Youn Jung et al. (2014) Crosstalk between the cGAS DNA sensor and Beclin-1 autophagy protein shapes innate antimicrobial immune responses. Cell Host Microbe 15:228-38|
|Bai, Zhiqiang; Huang, Yufei; Li, Wan et al. (2014) Genomewide mapping and screening of Kaposi's sarcoma-associated herpesvirus (KSHV) 3' untranslated regions identify bicistronic and polycistronic viral transcripts as frequent targets of KSHV microRNAs. J Virol 88:377-92|
|Knipe, David M; Lieberman, Paul M; Jung, Jae U et al. (2013) Snapshots: chromatin control of viral infection. Virology 435:141-56|
|Amini-Bavil-Olyaee, Samad; Choi, Youn Jung; Lee, Jun Han et al. (2013) The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13:452-64|
|Wong, Lai-Yee; Brulois, Kevin; Toth, Zsolt et al. (2013) The product of Kaposi's sarcoma-associated herpesvirus immediate early gene K4.2 regulates immunoglobulin secretion and calcium homeostasis by interacting with and inhibiting pERP1. J Virol 87:12069-79|
|Jung, Jae U; Speck, Samuel H (2013) Insights into chronic gamma-herpesvirus infections. Curr Opin Virol 3:225-6|
Showing the most recent 10 out of 11 publications